{"id":"NCT03541174","sponsor":"Idorsia Pharmaceuticals Ltd.","briefTitle":"A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety","officialTitle":"Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-18","primaryCompletion":"2021-05-14","completion":"2022-04-25","firstPosted":"2018-05-30","resultsPosted":"2023-03-21","lastUpdate":"2023-03-21"},"enrollment":730,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Resistant Hypertension"],"interventions":[{"type":"DRUG","name":"Aprocitentan 12.5 mg","otherNames":["ACT-132577"]},{"type":"DRUG","name":"Aprocitentan 25 mg","otherNames":["ACT-132577"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Aprocitentan 25 mg in Part 1 (double-blind)","type":"EXPERIMENTAL"},{"label":"Aprocitentan 12.5 mg in Part 1 (double-blind)","type":"EXPERIMENTAL"},{"label":"Placebo in Part 1 (double-blind)","type":"PLACEBO_COMPARATOR"},{"label":"Aprocitentan 25 mg in Part 2 (single-blind, single arm)","type":"EXPERIMENTAL"},{"label":"Aprocitentan 25 mg in Part 3 (double-blind withdrawal)","type":"EXPERIMENTAL"},{"label":"Placebo in Part 3 (double-blind withdrawal)","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of this clinical trial is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.","primaryOutcome":{"measure":"Change From Baseline to Week 4 of Double-blind Treatment in Mean Trough Sitting Systolic Blood Pressure (SiSBP) Measured by Automated Office Blood Pressure Measurement","timeFrame":"Pre-dose Day 1 (Part 1 double-blind randomized baseline) up to Week 4 (End of double-blind randomized part 1)","effectByArm":[{"arm":"Aprocitentan 12.5 mg in Part 1 (Double-blind)","deltaMin":-15.26,"sd":null},{"arm":"Aprocitentan 25 mg in Part 1 (Double-blind)","deltaMin":-15.2,"sd":null},{"arm":"Placebo in Part 1 (Double-blind)","deltaMin":-11.47,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0042"},{"comp":"OG001 vs OG002","p":"0.0046"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":7},"locations":{"siteCount":159,"countries":["United States","Australia","Belgium","Canada","China","Czechia","Finland","France","Germany","Greece","Hungary","Israel","Italy","Lithuania","Netherlands","Poland","Russia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["22595447","15699287","35686330","39840441","36356632"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":243},"commonTop":["Oedema peripheral"]}}